SEC Comment Letter 0000000000-24-001720 to CytoDyn Inc. (CYDY)
CytoDyn Inc.
Date: Feb. 13, 2024 · CIK: 0001175680 · Accession: 0000000000-24-001720
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276912
Letter
United States securities and exchange commission logo February 13, 2024 Mitchell Cohen Chief Financial Officer CytoDyn Inc. 1111 Main Street, Suite 660 Vancouver, Washington 98660 Re:CytoDyn Inc. Registration Statement on Form S-1 Filed February 7, 2024 File No. 333-276912 Dear Mitchell Cohen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mary Ann Frantz
Show Raw Text
United States securities and exchange commission logo
February 13, 2024
Mitchell Cohen
Chief Financial Officer
CytoDyn Inc.
1111 Main Street, Suite 660
Vancouver, Washington 98660
Re:CytoDyn Inc.
Registration Statement on Form S-1
Filed February 7, 2024
File No. 333-276912
Dear Mitchell Cohen:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mary Ann Frantz